Literature DB >> 19630771

Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?

D Lillicrap1.   

Abstract

Since the original description of this disease in 1926, major advances have been made in our understanding of the pathogenetic mechanisms responsible for von Willebrand disease (VWD). We now recognize that this disease comprises a collection of diverse quantitative and qualitative abnormalities of the adhesive protein von Willebrand factor (VWF), the key protein involved in platelet adhesion, and the carrier protein for factor VIII (FVIII) in plasma. Since the mid-1970s there has been a growing appreciation of 'variant' forms of the disease and in the 20 years since the cloning of the VWF gene, much progress has been made in characterizing the molecular genetic pathology of type 3 VWD and the various type 2 variants, types 2A, 2B, 2M and 2N VWD. In all of these cases, mechanistic insights into VWF structure/function have been forthcoming. Most recently, preliminary results relating to the mutational landscape of type 1 disease have been published that highlight the complex pathogenic background of this mild/moderate quantitative trait.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630771     DOI: 10.1111/j.1538-7836.2009.03367.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.

Authors:  Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol A Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

2.  Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort.

Authors:  Marco Campos; Wei Sun; Fuli Yu; Maja Barbalic; Weihong Tang; Lloyd E Chambless; Kenneth K Wu; Christie Ballantyne; Aaron R Folsom; Eric Boerwinkle; Jing-Fei Dong
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

3.  Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Authors:  Alexander Tischer; Pranathi Madde; Laurie Moon-Tasson; Matthew Auton
Journal:  Biophys J       Date:  2014-09-02       Impact factor: 4.033

4.  von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.

Authors:  Sri R Madabhushi; Chengwei Shang; Kannayakanahalli M Dayananda; Kate Rittenhouse-Olson; Mary Murphy; Thomas E Ryan; Robert R Montgomery; Sriram Neelamegham
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

5.  Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease.

Authors:  Hamideh Yadegari; Julia Driesen; Anna Pavlova; Arijit Biswas; Vytautas Ivaskevicius; Robert Klamroth; Johannes Oldenburg
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

6.  Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A.

Authors:  S L Sood; A Cuker; C Wang; A D Metjian; E Y Chiang; J M Soucie; B A Konkle
Journal:  Haemophilia       Date:  2013-03-28       Impact factor: 4.287

7.  Uncovering genomic causes of co-morbidity in epilepsy: gene-driven phenotypic characterization of rare microdeletions.

Authors:  Dalia Kasperavičiūtė; Claudia B Catarino; Krishna Chinthapalli; Lisa M S Clayton; Maria Thom; Lillian Martinian; Hannah Cohen; Shazia Adalat; Detlef Bockenhauer; Simon A Pope; Nicholas Lench; Martin Koltzenburg; John S Duncan; Peter Hammond; Raoul C M Hennekam; John M Land; Sanjay M Sisodiya
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

Review 8.  The molecular genetics of von Willebrand disease.

Authors:  Ergül Berber
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

9.  Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries.

Authors:  Conglei Li; June Li; Yan Li; Sean Lang; Issaka Yougbare; Guangheng Zhu; Pingguo Chen; Heyu Ni
Journal:  Adv Hematol       Date:  2012-09-12

10.  Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity.

Authors:  Y Ni; J Nesrallah; M Agnew; F J Geske; E J Favaloro
Journal:  Int J Lab Hematol       Date:  2012-10-29       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.